Ipca Laboratories announced a robust financial performance for Q2 and H1 FY26. Standalone Net Total Income increased by 7% to ₹1952.24 crores. Standalone Net Profit increased to ₹304.74 crores, up by 25%. The company experienced strong revenue growth in both domestic and export markets, contributing to overall profitability. Consolidated results also showed similar positive trends, reflecting the company’s strong operational performance and market position.
Key Financial Highlights
Ipca Laboratories has released its unaudited financial results for the second quarter (Q2) and first half (H1) of fiscal year 2026, showcasing strong financial performance across key metrics.
Standalone Performance
The standalone financial results reveal the following key highlights:
- Net Total Income: Increased by 7% to ₹1952.24 crores.
- EBITDA Margin: 25.46% compared to 22.89% in Q2 FY25.
- Net Profit: Increased by 25% to ₹304.74 crores.
- Earnings per share: ₹12.01 (Basic/Diluted)
Consolidated Performance
The consolidated financial results also demonstrate strong performance:
- Net Total Income: Increased by 9% to ₹2584.36 crores.
- EBITDA Margin: 21.68% compared to 19.10% in Q2 FY25.
- Net Profit: ₹282.57 crores.
Revenue Breakdown
A detailed breakdown of revenue sources for the quarter indicates:
- Domestic Formulations: ₹1018.90 crores, representing an increase of 8%.
- Export Formulations: ₹145.04 crores.
- API Revenue: ₹407.78 crores, a surge of 28%.
Half-Yearly Performance
The financial performance for the first half of FY26 (H1 FY26) is also encouraging:
- Standalone Net Total Income: Up by 9% to ₹3724.16 crores.
- Consolidated Net Total Income: Up by 10% to ₹4925.87 crores.
- Standalone Net Profit: ₹566.78 crores, up by 26%.
- Consolidated Net Profit: ₹515.78 crores, up by 22%.
About Ipca Laboratories
Ipca Laboratories is a pharmaceutical company focused on exports and vertically integrated for producing Finished Dosage Forms (FDFs) and Active Pharmaceutical Ingredients (APIs).
Source: BSE
